DIALysis With EXpanded Solute Removal
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is: 1\) Does expanded hemodialysis reduce the risk of death from any cause? Researchers will compare expanded hemodialysis to conventional hemodialysis (the
| Condition(s) | Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), Chronic Kidney Disease Requiring Chronic Dialysis, Pragmatic Randomized Controlled Trial, Kidney Disease, Renal Insuffic |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is: 1\) Does expanded hemodialysis reduce the risk of death from any cause? Researchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes. Participants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux/expanded dialysis filter or a high-flux/conventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare |
| Who can participate | Inclusion Criteria: Inclusion requires that all the following are present: 1. One of: 1. Age 60 years or older; or 2. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and 2. Receiving any form of dialysis regularly for the previous 90 days; and 3. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and 4. A valid provincial or territorial health insurance card number. Exclusion Criteria: Patients are ineligible if they meet any of the following criteria: 1. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of: 1. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or 2. Planned to receive HDF; or 3. Planned to recei |
| Ages | 45 Years |
| Sex | All |
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Locations | London, Ontario, Canada |
| Start date | 2025-08-12 |
| NCT ID | NCT06660277 |
| Official listing | https://clinicaltrials.gov/study/NCT06660277 |